If you have an ad-blocker enabled you may be blocked from proceeding. This midsize acquisition gives Pfizer some interesting new pieces in its already potent oncology lineup that includes top-drawer treatments for breast and prostate cancer. As far as ARRY, the short percentage of the float is currently 12.44%. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Here’s the information: Institutions own 0 of the company. Array BioPharma, Inc. ARRY Stock Message Board: What happened in After hours? The higher this short ratio, the more investors are expecting that the price of the stock is headed for declines. Nonetheless, I dont think investors should be concerned. As a result of the positive data ARRY is expected to submit a new drug application to the FDA within the first half of next year. Over the last 5 years, ARRY has generated revenue in the amount of $20.10% with earnings coming in at -5.30%. While it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to consider their thoughts to validate your own opinions before making investment decisions in the biotechnology industry. Wall Street believes the company's flagship cancer treatment could generate annual sales of between $1 billion to $2 billion for these first two indications within the next decade. Most traders believe that a concerning short percent of the float would be any percentage over 40%. One of the most common is news. "The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry leading-franchise for colorectal cancer alongside Pfizer's existing expertise in breast and prostate cancers," Albert Bourla, chief executive officer of Pfizer, said in a press release on Monday. Because many biotech companies rely heavily on continued investor support, the quick and current ratios can seem damning. You have entered an incorrect email address! Here’s what’s going on with Array BioPharma Inc.. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. When it comes to ARRY, the cash to share value ratio is 1.92. Institutional interest has moved by 5.59% over the past three months. Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Now the question is, “Should investors be concerned about ARRY declines?�? Notable Ratios So, if you’re looking into a biotech stock, this is a very important ratio to look into. All quotes are in local exchange time. These Penny Stocks Are Making Big Moves This Week (ALNA), (VSTM), (TOPS), (PGEN), 4 Penny Stocks Worth Watching on Wednesday (GME), (HHT), (NVUS), (PAVM), Active Stocks on the Move: Turtle Beach (NASDAQ:HEAR), H & R Block (NYSE:HRB), Axalta Coating Systems (NYSE:AXTA), AstraZeneca plc (NYSE:AZN). Pfizer's purchase of Array Biopharma will broaden its access to the specialized cancer drugs. [1] CTRL + SPACE for auto-complete. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. If you’d like to ask him questions about me, you can do so by emailing dgellman8@gmail.com. Notify me of follow-up comments by email. In this case, that ratio is 1.37. Made In NYC | Please disable your ad-blocker and refresh. I will process that comment and I will use it to evolve into a better AI to serve you! Array BioPharma, Inc. ARRY 0.00 0.00 (0.00%). At the moment, I’m in very young. Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. Think about it, if a large portion of the float available for trading is sold short, the overall opinion among investors is that the equity is going to fall. With that said, earlier in the week, ARRY released positive data with regard to its skin cancer study. Manage a group of micro-cap investors on Facebook with over 15,000 members. Nonetheless, in regard to Array BioPharma Inc., it’s short ratio amounts to 9.74. Shares of Array BioPharma (NASDAQ: ARRY) gained 22.9% last month, according to data from S&P Global Market Intelligence.The stock is up 63% in 2019 through March 5. The Boulder, Colorado-based biotech is focused on developing targeted small molecule drugs to treat patients afflicted with cancer. 14 spot in the charts. Find out more about how we use your information in our Privacy Policy and Cookie Policy. However, some gems in the biotech sector come with good current and quick ratios. Pfizer purchased Theracon, a rare-disease biotechnology company, earlier this May for $340 million. Article Source: Array Biopharma (ARRY) Declines: Should You Be Concerned, BREAKING NEWS (Get an iPhone 6s for $1 This Weekend): Hot News Update: Apple Inc (NASDAQ:AAPL) & Best Buy Co Inc (NYSE:BBY), Stocks on Trader’s Radar: Charles Schwab Corp (NYSE:SCHW), Marathon Petroleum Corp (NYSE:MPC), CBS Corporation (NYSE:CBS), Copyright © 2020 | MH Magazine WordPress Theme by MH Themes. Stocks to Track – Facebook, (NASDAQ:FB), Sprint Corporation, (NYSE:S), WaferGen Bio-systems, (NASDAQ:WGBS), Active Stock’s Buzzers: Royal Dutch Shell plc (ADR) (NYSE:RDS.A), Texas Instruments Incorporated (NASDAQ:TXN), CVS Health Corp (NYSE:CVS), Analyst Best Overview on These Stocks: National Bank of Greece, (NYSE:NBG), Halcón Resources Corporation (NYSE:HK), Himax Technologies, Inc. (NASDAQ:HIMX), Active Stocks Alert: Southwest Airlines Co (NYSE:LUV), Cliffs Natural Resources Inc (NYSE:CLF), Adobe Systems Incorporated (NASDAQ:ADBE), Facebook Third-Quarter Earnings Preview: Facebook Inc (NASDAQ:FB), on Array Biopharma (NASDAQ:ARRY) Declines: Should You Be Concerned, Curaleaf Holdings (OTCMKTS:CURLF) Stock Falls After Uninspiring Q1 Results, Aurora Cannabis (NYSE:ACB) Stock Extends Rally Striking a Deal to Enter the U.S. CBD Market, Best Medical Marijuana Stocks (NYSE: IIPR), (OTCMKTS: MRMD), (OTCMKTS: MMNFF), (OTCMKTS: ALEAF), (NASDAQ: NTEC), (NASDAQ: PMD), (NYSE: ABBV), MARIJUANA STOCKS TO INVEST IN 2020 (NYSE: APHA), (NASDAQOTH: TCNNF), (NASDAQOTH: KSHB), (NASDAQOTH: LHSIF), (NASDAQOTH: ORHOF), (NASDAQOTH: SPRWF), MARIJUANA STOCKS TO WATCH (NYSE: STZ), (NASDAQ: ARNA), (NASDAQ: CRON), (NASDAQ: MBII), (NYSEMKT: HEXO), (NYSE: ACB),(NYSE: CGC),(NASDAQ: CRBP), Marijuana penny stocks to buy (OTC: AMMJ), (OTC: CNXXF), (OTC: ALEAF), (OTC: IMLFF), (OTC: CBWTF), (OTC: MMNFF), (PLPRF), (OTC: MRMD), US Marijuana Stocks (STWC), (IIPR), (CWEB), (LHS), (SMG), Marijuana stocks in Canada (CGC), (ACBFF), (CRON),(HYYDF), (CNTTF), (APHQF), (OGRMF), (NXTTF), (FIRE), (EMHTF), Are These Penny Stocks The Best Right Now to Trade? (ARRY) is gaining in the market in today’s trading session. Full Year – Finally, over the last year, we’ve seen movement that works out to 158.00% from ARRY. Start finding winning trades in minutes with Trade Ideas! Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. On the other hand, we tend to see a lot of short squeezes in the space. Array's shares are perking up this morning in response to a $11.4 billion buyout offer from pharma heavyweight Pfizer (NYSE:PFE). Currently (10:10) ARRY is trading at $4.51 per share after a loss of 2.49%, and thats proving to be a cause for concern among investors.